[1]Allen TM.Ligand-targeted therapeutics in anticancer therapy[J].Nat Rev Cancer,2002,2(10):750-763.
[2]Dubowchik GM,Walker MA.Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs[J].PharmTher,1999,83(2):67-123.
[3]Dwek RA.Glycobiology:Toward understanding the function ofsugars[J].Chem Rev,1996,96(2):683-720.
[4]Drickamer K,TAYLOR ME.Biology of animal lectins[J].AnnuRev Cell Biol,1993,9:237-264.
[5]Paillard F.Glycotargeting:A receptor-mediated delivery usingsugar ligands[J].Hum Gene Ther,1999,10(3):337-339.
[6]Wadhwa MS,Rice KG.Receptor mediated glycotargeting[J].JDrug Target,1995,3(2):111-127.
[7]Zhang H,Ma Y,Sun XL.Recent developments in carbohydrate-decorated targeted drug/gene delivery[J].Med Res Rev,2010,30(2):270-289.
[8]Sharon N,Lis H.Lectins as cell recognition molecules[J].Sci,1989,246(4927):227-234.
[9]Monsigny M,Roche AC,Kieda C,et al.Characterization and bio-logical implications of membrane lectins in tumor,lymphoid andmyeloid cells[J].Biochimie,1988,70(11):1633-1649.
[10]Gorelik E,Galili U,Raz A.On the role of cell surface carbohy-drates and their binding proteins(lectins)in tumor metastasis[J].Cancer Metastasis Rev,2001,20(3-4):245-77.
[11]Raz A,Lotan R.Endogenous galactoside-binding lectins:A newclass of functional tumor cell surface molecules related to metasta-sis[J].Cancer Metastasis Rev,1987,6(3):433-452.
[12]Weiss P,Ashwell G.The asialoglycoprotein receptor:Propertiesand modulation by ligand[J].Prog Clin Biol Res,1989,300:169-184.
[13]Park EI,Mi Y,Unverzagt C,et al.The asialoglycoprotein receptorclears glycoconjugates terminating with sialic acid alpha 2,6GalNAc[J].Proc Natl Acad Sci USA,2005,102(47):17125-17129.
[14]Lee RT.Ligand structural requirements for recognition and bind-ing by the hepatic asialoglycoprotein receptor[J].Targeted DiagnTher,1991,4:65-86.
[15]Kolatkar AR,Leung AK,Isecke R,et al.Mechanism of N-acetylgalactosamine binding to a C-type animal lectin carbohy-drate-recognition domain[J].J Biol Chem,1998,273(31):19502-19508.
[16]Schwartz AL.The hepatic asialoglycoprotein receptor[J].CRCCrit Rev Biochem,1984,16(3):207-233.
[17]Drickamer K.Evolution of Ca(2+)-dependent animal lectins[J].Prog Nucleic Acid Res Mol Biol,1993,45:207-232.
[18]蔡春.Gal-HAS-5-Fu的合成、肝靶向作用和抗癌活性初探[D].成都:四川大学博士学位论文,2006:1-168.
[19]Barondes SH,Castronovo V,Cooper DN,et al.Galectins:a familyof animal beta-galactoside-binding lectins[J].Cell,1994,76(4):597-598.
[20]Rapoport EM,Kurmyshkina OV,Bovin NV.Mammalian galec-tins:Structure,carbohydrate specificity,and functions[J].Bio-chemistry(Mosc),2008,73(4):393-405.
[21]Nakahara S,Raz A.Biological modulation by lectins and their lig-ands in tumor progression and metastasis[J].Anticancer AgentsMed Chem,2008,8(1):22-36.
[22]Hirabayashi J,Hashidate T,Arata Y,et al.Oligosaccharide spe-cificity of galectins:A search by frontal affinity chromatography[J].Biochim Biophys Acta,2002,1572(2-3):232-254.
[23]Bartolazzi A,Orlandi F,Saggiorato E,et al.Galectin-3-expression analysis in the surgical selection of follicular thyroidnodules with indeterminate fine-needle aspiration cytology:Aprospective multicentre study[J].Lancet Oncol,2008,9(6):543-549.
[24]Ozaki K,Inoue K,Sato H,et al.Functional variation in LGALS2confers risk of myocardial infarction and regulates lymphotoxin-alpha secretion in vitro[J].Nature,2004,429(6987):72-75.
[25]Huflejt ME,Leffler H.Galectin-4 in normal tissues and cancer[J].Glycoconj J,2004,20(4):247-255.
[26]Bidon-Wagner N,LE Pennec JP.Human galectin-8 isoformsand cancer[J].Glycoconj J,2004,19(7-9):557-563.
[27]Hsu DK,Yang RY,Pan Z,et al.Targeted disruption of thegalectin-3 gene results in attenuated peritoneal inflammatoryresponses[J].Am J Pathol,2000,156:1073-1083.
[28]Nakamura M,Inufusa H,Adachi T,et al.Involvement ofgalectin-3 expression in colorectal cancer progression and metas-tasis[J].Int J Oncol,1999,15(1):143-148.
[29]Tsuboi K,Shimura T,Masuda N,et al.Galectin-3 expression incolorectal cancer:Relation to invasion and metastasis[J].Anti-cancer Res,2007,25:2289-2296.
[30]Rabinovich GA,Toscano MA,Jackson SS,et al.Functions of cellsurface galectin-glycoprotein lattices[J].Curr Opin StructBiol,2007,17(5):513-520.
[31]黄海涛,姜茹,梅其炳,等.3-全乙酰化半乳吡喃糖基-5-氟尿嘧啶的合成及其体外抗肿瘤活性研究[J].中国药理学通报,2011,27(12):1710-1713.
[32]Bertozzi CR.Cracking the carbohydrate code for selectin recogni-tion[J].Chem Biol,1995,2(11):703-708.
[33]Cooke RM,Hale RS,Lister SG,et al.The conformation of thesialyl Lewis X ligand changes upon binding to E-selectin[J].Biochemistry,1994,33(35):10591-10596.
[34]Onrust SV,Hartl PM,Rosen SD,et al.Modulation of L-selectinligand expression during an immune response accompanyingtumorigenesis in transgenic mice[J].J Clin Invest,1996,97(1):54-64.
[35]Narita T,Kawakami-Kimura N,Kasai Y,et al.Induction ofE-selectin expression on vascular endothelium by digestive sys-tem cancer cells[J].J Gastroenterol,1996,31(2):299-301.
[36]Isacke CM,Yarwood H.The hyaluronan receptor,CD44[J].Int JBiochem Cell Biol,2002,34(7):718-721.
[37]Bajorath J,Greenfield B,Munro SB,et al.Identification of CD44residues important for hyaluronan binding and delineation of thebinding site[J].J Biol Chem,1998,273(1):338-343.
[38]Peer D,Park EJ,Morishita Y,et al.Systemic leukocyte-directedsiRNA delivery revealing cyclin D1 as an anti-inflammatory tar-get[[J].Sci,2008,319(5863):627-630.
[39]Yang B,Yang BL,Savani RC,et al.Identification of a commonhyaluronan binding motif in the hyaluronan binding proteinsRHAMM,CD44 and link protein[J].EMBO J,1994,13(2):286-296.
[40]Hall CL,Yang B,Yang X,et al.Overexpression of the hyaluronanreceptor RHAMM is transforming and is also required for H-rastransformation[J].Cell,1995,82(1):19-26.
[41]Gust KM,Hofer MD,Perner SR,et al.RHAMM(CD168)is over-expressed at the protein level and may constitute an immunogenicantigen in advanced prostate cancer disease[J].Neoplasia,2009,11(9):956-963.
